Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study - 14/01/19
, Sigrun Alba Johannesdottir Schmidt, PhD d, Lisbet Rosenkrantz Hölmich, DMSc e, Søren Friis, MD d, f, g, Anton Pottegård, PhD c, David Gaist, PhD a, bAbstract |
Background |
Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST).
Objective |
To examine the association between hydrochlorothiazide use and the risk for MCC and MAST.
Methods |
Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of hydrochlorothiazide.
Results |
The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0), respectively, which increased to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95% CI 0.9-4.0).
Limitations |
No data on sun exposure was available.
Conclusion |
Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.
Le texte complet de cet article est disponible en PDF.Key words : antihypertensives, epidemiology, hydrochlorothiazide, malignant adnexal skin tumors, Merkel cell carcinoma, pharmacology, skin cancer
Abbreviations used : CI, OR, UV
Plan
| Funding sources: Supported by a grant from the Danish Cancer Society (grant R72-A4417) and the Danish Council of Independent Research (grant 4004-00234B). The funding source had no role in the design of the study, data analysis, or interpretation of the results. |
|
| Conflicts of interest: Dr Gaist received honoraria from AstraZeneca (Sweden) for participating as a coinvestigator in a research project outside this work. Dr Pottegård has participated in research projects unrelated to the present study using grants provided by LEO Pharma (manufacturer of bendroflumethiazide) to the institution where he was employed. The remaining authors disclose no relevant conflicts of interest. |
Vol 80 - N° 2
P. 460 - février 2019 Retour au numéro
Article précédent
- Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study
- Feras M. Ghazawi, Janelle Cyr, Rami Darwich, Michelle Le, Elham Rahme, Linda Moreau, Elena Netchiporouk, Andrei Zubarev, Osama Roshdy, Steven J. Glassman, Denis Sasseville, Ivan V. Litvinov
- Comorbidities in alopecia areata: A systematic review and meta-analysis
- Solam Lee, Hanil Lee, Chung Hyeok Lee, Won-Soo Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?